European approval for lung cancer drug Imfinzi

The European Commission has granted marketing authorization for Imfinzi (durvalumab) as monotherapy for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 on ≥1% of tumor cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy (CRT).

Granted to Anglo-Swedish pharma major AstraZeneca (LSE: AZN), the approval is based on results from the Phase III PACIFIC trial, and follows the positive opinion on 27 July 27, 2018 from the European Medicines Agency’s advisory committee.

Only immunotherapy to be approved in this setting